Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – Cizzle Biotechnology said on Tuesday it has raised £150,000 ($200,635) to support the rollout of its lung cancer early detection test in the UK and other European countries.

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

Healthcare Royalty Partners purchased anticipated royalties and milestone payments, and Regenxbio received $150 upfront at closing.

NEW YORK – CRISPR Therapeutics and Sirius Therapeutics have inked a deal valued at up to $95 million to develop and commercialize small interfering RNA therapies, starting with a treatment for ...

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

The analysis by Ontada tracked testing rates within the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 ...

Moving forward, the biotech said it will focus its resources on developing treatments for genetic liver diseases and on its partnered programs.

The treatment has been used in a trial to treat children with GM1 gangliosidosis, but if the FDA allows, this would be the ...

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...

The baby boy with a rare urea cycle disorder received the bespoke therapy within a few months of birth and is doing well, ...

The firms launched the global Phase II bladder cancer trial for autogene cevumeran after seeing early success in pancreatic ...